Azzad Asset Management’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Azzad Asset Management’s Portfolio CSCI Stock Details CSCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-3	Closed	-$2.36K	–	259
2015 Q3	$2.36K	Buy	3 +1	+50%	+$1.46K	﹤0.01%	246
2015 Q2	$6.08K	Hold	2	–	–	﹤0.01%	253
2015 Q1	$9.4K	Hold	2	–	–	﹤0.01%	260
2014 Q4	$9.3K	Buy	+2	New	+$16.8K	﹤0.01%	274
2014 Q3	–	Sell	-1	Closed	-$14.3K	–	298
2014 Q2	$14.3K	Buy	+1	New	+$11.2K	0.01%	270

Other funds holding CSCI

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Azzad Asset Management's CSCI Position: Q4 2015 in Review

Azzad Asset Management sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q4 2015, closing a stake of 3 shares — an estimated $2.36K sold.

Azzad Asset Management first reported a position in CSCI in Q2 2014 and held it in 5 quarters. The position peaked at $14.3K in Q2 2014. 17 funds tracked by Wall St. Rank hold CSCI as of Q4 2015.

Azzad Asset Management reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
Azzad Asset Management sold 3 COSCIENS Biopharma Inc. Common Stock shares in Q4 2015, an estimated $2.36K.
Azzad Asset Management first reported a position in COSCIENS Biopharma Inc. Common Stock in Q2 2014 and held it in 5 quarters.
Azzad Asset Management's COSCIENS Biopharma Inc. Common Stock position peaked at $14.3K in Q2 2014.
17 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q4 2015.

Based on Azzad Asset Management's 13F filing for Q4 2015, filed 3 Apr 2024.